SLC6A3 and attention deficit-hyperactivity disorder: MPH exerts its therapeutic effect by blocking the function of the DA transporter (DAT) and norepinephrine transporter [NET, thereby increasing the bioavailability of the neurotransmitters and correcting the deficit thought to cause ADHD (16–18)].